Who Paid My Doc
Photofrin
Drug Oncology
NDC 76128-155-75
General payments
$1,058,284
Research payments
$799,514
Through program year 2025, $1,058,284 in general payments and $799,514 in research payments were reported against Photofrin (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
10 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $87,965 | 376 |
| 2024 | General | $70,646 | 342 |
| 2023 | General | $155,855 | 374 |
| 2022 | General | $235,026 | 843 |
| 2021 | General | $166,727 | 471 |
| 2021 | Research | $111,550 | 3 |
| 2020 | General | $84,380 | 242 |
| 2020 | Research | $72,427 | 14 |
| 2019 | General | $257,687 | 918 |
| 2019 | Research | $615,537 | 49 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 27 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 33 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
3,566 general · 66 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.